Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909986 | 0.86 | CTSS (0.59) | CTSSCTSKCTSBCTSLPPARG | |
| SCHEMBL478788 | 0.86 | EPHX2 (0.41) | CTSSCTSKFPR2GPR34PPARG | |
| SCHEMBL20608683 | 0.76 | SIRT2 (0.39) | CTSSCTSKFPR2PIN1 | |
| SCHEMBL20608682 | 0.76 | SIRT2 (0.39) | CTSSCTSKFPR2PIN1 | |
| SCHEMBL3416318 | 0.74 | L3MBTL1 (0.47) | FPR2ALDH1A1LMNA | |
| SCHEMBL23356941 | 0.74 | SLC1A1 (0.54) | CTSSCTSKSLC1A1ROCK1 | |
| SCHEMBL23356943 | 0.74 | SLC1A1 (0.54) | CTSSCTSKSLC1A1ROCK1 | |
| SCHEMBL7362177 | 0.72 | L3MBTL1 (0.51) | FPR2GPR34 | |
| SCHEMBL6372232 | 0.72 | TACR1 (0.55) | CTSSCTSKSLC1A1ALDH1A1LMNA | |
| SCHEMBL27552216 | 0.72 | TACR1 (0.55) | CTSSCTSKSLC1A1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | CTSS 541/4885CTSK 273/4885FPR2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.